category,datetime,headline,id,image,related,source,summary,url
company,1768606560,"AbbVie Call Options Spike 2,599%: Tracking the Big Bet",138165133,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,ABBV,Yahoo,Large institutional investors are positioning for growth as a leading biopharmaceutical firm enters the obesity market and reaches a federal agreement.,https://finnhub.io/api/news?id=996a062c6dd1590ff36d2e1940f8f304ccc189fce3d226b5f0e919334548f399
company,1768592880,Emmecell Appoints Ramin Valian as Chief Executive Officer to Advance Magnetic Cell Delivery Platform,138155353,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,ABBV,Yahoo,"MENLO PARK, Calif., January 16, 2026--Emmecell announces the appointment of ophthalmology leader Ramin Valian as CEO.",https://finnhub.io/api/news?id=2fa5e2aa0c4ac6ecab8867dd072b729a8d22d06b542891341c1ad4ca827445df
company,1768588980,AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL),138155354,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,ABBV,Yahoo,"AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator's choice of chemoimmunotherapy in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The study demonstrated an improvement in progression-free survival (PFS) (HR: 0.74 [95% CI 0.60 to 0.92])*. Improvements were observed in complete response rates (CRR), durat",https://finnhub.io/api/news?id=4f51da30e4cbd7a41e182fcd608706c5aaf4b89b086fbe3e8e7229290768650e
company,1768572600,"AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival",138207765,,ABBV,MarketWatch,"AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival",https://finnhub.io/api/news?id=53361895dc2111b56d204b4b5d13d7381467beb3641ce00855688248622911ca
company,1768571620,JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency,138151714,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,ABBV,Yahoo,"AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology pipeline.",https://finnhub.io/api/news?id=6eec269a780b992e9ff22b62296f1dde50dd508b49e2c088df3adf406bd0a3f2
company,1768566535,Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data,138153628,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1306234498/image_1306234498.jpg?io=getty-c-w1536,ABBV,SeekingAlpha,"Ocugen, Inc. gene therapy outlook: key 2026 catalysts, Phase 2/3 eye-disease data, BLA plans to 2028, and risks. Click for this OCGN update.",https://finnhub.io/api/news?id=3a4f532118ffd7eac05a221904dad80cd2cb3c0e196b8e53fd28359fd7d53728
company,1768561220,AbbVie Inc.'s (NYSE:ABBV) institutional investors lost 3.3% last week but have benefitted from longer-term gains,138150986,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,ABBV,Yahoo,Key Insights Institutions' substantial holdings in AbbVie implies that they have significant influence over the...,https://finnhub.io/api/news?id=6600ee6eec918eb65d7841523891ad0a507293eef015f2b021f5c5a602183fab
